Feasibility of a clinical trial to assess the effect of dietary calcium v. supplemental calcium on vascular and bone markers in healthy postmenopausal women

Angel M. Ong1,2, Hope A. Weiler2, Michelle Wall1, Rouba Haddad3, Jessica Gorgui1, Stella S. Daskalopoulou1,4, David Goltzman1,4 and Suzanne N. Morin1,4*

1Research Institute, McGill University Health Centre, Montreal, QC, Canada, H3G 1A4
2School of Dietetics and Human Nutrition, McGill University, Ste-Anne-de-Bellevue, QC, Canada, H9X 3V9
3Department of Nutrition, Shriners Children’s Hospital, Montreal, QC, Canada, H3G 1A6
4Department of Medicine, McGill University, Montreal, QC, Canada, H3A 3J1

(Submitted 10 November 2015 – Final revision received 11 February 2016 – Accepted 28 March 2016 – First published online 16 May 2016)

Abstract
Whether supplemental Ca has similar effects to dietary Ca on vascular and bone markers is unknown. The present trial investigated the feasibility of applying dietary and supplemental interventions in a randomised-controlled trial (RCT) aiming to estimate the effect of supplemental Ca as compared with dietary Ca on vascular and bone markers in postmenopausal women. In total, thirteen participants were randomised to a Ca supplement group (CaSuppl) (750 mg Ca from CaCO3 + 450 mg Ca from food + 20 µg vitamin D supplement) or a Ca diet group (CaDiet) (1200 mg Ca from food + 10 µg vitamin D supplement). Participants were instructed on Ca consumption targets at baseline. Monthly telephone follow-ups were conducted to assess adherence to interventions (±20% of target total Ca) using the multiple-pass 24-h recall method and reported pill count. Measurements of arterial stiffness, peripheral blood pressure and body composition were performed at baseline and after 6 and 12 months in all participants who completed the trial (n = 9). Blood and serum biomarkers were measured at baseline and at 12 months. Both groups were compliant to trial interventions (±20% of target total Ca intake; pill count ≥80%). CaSuppl participants maintained a significantly lower average dietary Ca intake compared with CaDiet participants throughout the trial (453 (SD 187) mg/d vs. 1241 (SD 319) mg/d; P < 0.001). There were no significant differences in selected vascular outcomes between intervention groups over time. Our pilot trial demonstrated the feasibility of conducting a large-scale RCT to estimate the differential effects of supplemental and dietary Ca on vascular and bone health markers in healthy postmenopausal women.

Key words: Dietary interventions; Calcium; Arterial stiffness; Postmenopausal women

Adequate intakes of Ca and vitamin D are essential for optimal bone health throughout adulthood to prevent osteoporosis and related fractures (1–6). Current dietary reference intakes for Ca have been established by the Institute of Medicine for women over 50 years of age – that is, the Estimated Average Requirement (EAR), RDA and Tolerable Upper Intake Level (UL) are 1000, 1200 and 2000 mg/d, respectively (7). However, adequate intake of Ca can be difficult to achieve through dietary sources alone (8,9). According to the National Health and Nutrition Examination Survey 2003–2006 data, less than 10% of American women over 50 years of age reached an intake of 1200 mg/d of Ca from food alone (8). Similarly, over 80% of Canadian women over 50 years of age had a Ca intake <1000 mg/d from dietary sources according to the 2004 Canadian Community Health Survey (9). Thus, to ensure adequate total Ca intake for skeletal integrity, Ca supplements are widely recommended (10,11). Collectively, data from North America documented that 49–67% of women aged 50–70 years and 60–65% of those over 71 years of age reported using supplements that contain Ca (8,9).

Ca supplementation is generally well tolerated but can be associated with mild gastrointestinal symptoms and with renal lithiasis (12). More recently, concerns about the use of supplemental Ca have been expressed following the publication of two meta-analyses, which reported that Ca supplementation, with or without vitamin D, increased the risk of cardiovascular events, particularly myocardial infarctions (13,14). However, other analyses in similar populations have not reported this adverse association between Ca supplementation and

Abbreviations: 25(OH)D, 25-hydroxy vitamin D; CaDiet, Ca diet group; cfPWV, carotid-femoral pulse wave velocity; crPWV, carotid-radial pulse wave velocity; CaSuppl, Ca supplement group; PTH, parathyroid hormone; PWV, pulse wave velocity.

* Corresponding author: Dr S. N. Morin, fax +1 514 937 7298, email suzanne.morin@mcgill.ca
Feasibility study of calcium interventions

Cardiovascular events (15–16). On the other hand, most studies demonstrated that dietary sources of Ca have not been linked with cardiovascular adverse events (13,19,20) or have been shown to be favourable to cardiovascular health (21–24). However, a recent report has raised uncertainty associating milk intake with cardiovascular adverse events (13,19,20) or have been shown demonstrated that dietary sources of Ca have not been linked with cardiovascular mortality rate, particularly cardiovascular death, in a large cohort of men and women over a 20-year period (25).

CVD is a leading cause of morbidity and mortality globally in women after the age of 50 years, with coronary artery disease and stroke representing 23 and 18% of cause of death, respectively (20,27). In practice, early damage to the vascular system can be assessed non-invasively and accurately by measuring arterial stiffness, a composite indicator of vascular health that is an independent predictor of CVD and cardiovascular events (28,29). However, limited evidence exists on the effect of either supplemental or dietary Ca intake on arterial stiffness.

We conducted a 12-month pilot trial to determine the feasibility of controlled dietary and supplemental interventions of a randomised-controlled trial that aims to assess the effect of supplemental Ca as compared with dietary Ca on arterial stiffness and other vascular and bone markers in postmenopausal women. The primary objectives were to test the feasibility of nutritional counselling on adherence to the dietary and supplemental interventions, and the tolerability of Ca and vitamin D supplementation. The secondary exploratory objective was to contribute preliminary evidence on the effect of dietary Ca vs. supplemental Ca on vascular and bone health markers.

Methods

Study design and population

We conducted a randomised, single-blinded, parallel, 1-year intervention trial from May 2012 to January 2014. Healthy postmenopausal women aged 55 years and older (≥5 years since last menstrual period) without any chronic disease were recruited through posters and local newspaper advertisements in Montreal, Quebec, and were screened for eligibility by phone. Exclusion criteria were established to avoid including women with clinical or subclinical vascular impairment due to cardiovascular risk factors or CVD. Specifically, postmenopausal women with lactase intolerance were excluded, as were those who smoked within the last 5 years, who had a BMI <20 or ≥30 kg/m², history of diabetes, pre-eclampsia, hypertension, atrial fibrillation or atherosclerosis. Participants who had used hormonal replacement therapy (excluding vaginal preparations) in the last 3 years, medications to treat hypertension or hypercholesterolaemia or medications known to affect bone metabolism (systemic glucocorticoids, bisphosphonates, receptor activator of NF-κB ligand inhibitor, selective oestrogen receptor modulators, calcitonin, teriparatide) within the past 12 months were also excluded. Those with a 10-year absolute risk of major osteoporotic fractures >20%, computed using FRAX® without bone mineral density, were excluded as well (30). All participants were required to refrain from using nutritional supplements for 2 months before study entry. The present trial was conducted according to the guidelines laid down in the Declaration of Helsinki, and ethics approval was granted by the McGill University Health Centre Research Ethics Board. Written informed consent was obtained from all participants (GEN-11-231).

On-site visits occurred at baseline and at 6 and 12 months after randomisation at the same research site. Participants were asked to abstain from vigorous physical activity and alcohol consumption for 48 h and to fast overnight for 12 h before their visit. Participants were randomised to one of two interventions on the day of the baseline visit. A web-based patient randomisation service (http://www.randomizer.at) was used to generate permuted block randomisation in six-block intervals. The interventions were as follows: Ca supplement group (CaSuppl), 750 mg Ca carbonate supplement (Euro-Ca; Euro-Pharm International Canada Inc.) + 450 mg from food sources + vitamin D supplement of 20 µg (800 IU) daily or Ca diet group (CaDiet), 1200 mg of Ca from food sources + vitamin D supplement of 10 µg (400 IU) daily. Although very few foods naturally contain vitamin D, the CaDiet supplies 10 µg (400 IU) of dietary vitamin D from fluid milk and alternative plant-based beverages enriched with Ca, which are fortified with vitamin D in Canada.

Participants randomised to the CaSuppl arm were instructed by the research dietician to limit their daily intake of dairy products and alternative Ca-rich foods to one small portion (providing approximately 150 mg serving). Participants randomised to the CaDiet arm were instructed to increase their intake of dairy products and alternative Ca-rich foods to three portions a day (providing approximately 300 mg serving). A total daily intake of 1200 mg of Ca, which included 300 mg of Ca from other foods in the diet, such as vegetables and grains (31), was obtained from the combination of supplementation and dietary sources in the CaSuppl group, and through dietary sources alone in the CaDiet group. Instructions on how to estimate portion sizes were provided at the baseline visit by the dietician using food models and common household items. Educational tools including the Calcium Calculator® by the British Columbia Dairy Foundation (32), the nutrition label reading handout by Health Canada (33) and sample menus were provided. Participants received monthly follow-up telephone calls to monitor health status, adverse events and compliance to the assigned intervention.

Measurements

Measures of feasibility. The primary outcome measures for this pilot trial include participant adherence to the trial protocol and compliance to trial interventions, as well as tolerability of Ca and vitamin D supplementation. Compliance to trial interventions was defined as a mean total Ca intake ±20% of target (i.e. 1200 ± 240 mg), as per intervention assignment, and use of Ca supplements ≥ 80%. Tolerability of supplements was assessed by reported adverse events, and acceptability of measurements was assessed by direct questioning by research personnel.
**Questionnaires.** Past medical history and family history of CVD and bone disease were surveyed at the baseline visit, as well as use of medications and nutritional supplements. The International Physical Activity Questionnaire (IPAQ)\(^\text{34,35}\) and the Harvard–Willett FFQ\(^\text{36}\) were administered at baseline and at 12 months to estimate physical activity status and to determine nutrient intakes, respectively. Participants were asked to report the time they spent on specific types of physical activities in the last 7 d. Metabolic equivalents were calculated based on the activity type as per the IPAQ guidelines\(^\text{37}\). A trained research member administered the FFQ, which was based on the participant’s usual intake in the last 3 months. Multiple-pass 24-h recalls\(^\text{38}\) were administered at each on-site visit and at each monthly telephone follow-up. FFQ data were analysed using the Canadian Nutrient File 2010b to calculate energy, Ca and vitamin D intakes. The 24-h recall data were analysed using Nutritionist Pro software (Axxya Systems) to calculate dietary Ca and vitamin D intakes and monitor adherence to the dietary interventions. Supplementation compliance was assessed by reported tablet count during monthly follow-up calls and by verification of reported tablet count upon return of supplement bottles. General health status, use of new medications and nutritional supplements were also surveyed during monthly follow-ups.

**Anthropometric measurements.** Height, weight and waist and hip circumferences were measured at each visit using standard practices. Standing height was measured to the nearest 0.1 cm using a wall-mounted stadiometer (Seca 242), and weight was measured to the nearest 0.1 kg in light clothing without shoes (Tanita TBF-310; Tanita Corp.). Waist circumference was measured to the nearest 0.5 cm at the midpoint between the lower costal margin and the iliac crest according to Health Canada guidelines\(^\text{39}\). Hip circumference was measured to the nearest 0.1 cm at the level of the symphysis pubis and the greatest gluteal protuberance based on the protocol followed by Health Canada, the *Canadian Standard Test of Fitness*, 3rd edition\(^\text{40}\).

**Vascular measurements.** Peripheral resting blood pressure was measured using the automated BpTRU device (BpTRU Medical Devices Inc.), according to the Canadian Hypertension Education Program guidelines\(^\text{41}\). Arterial stiffness assessments were performed with the participant in the supine position after a 10-min rest period in a quiet, temperature-controlled (20 ± 1°C) and humidity-controlled (60 ± 5%) environment (Vascular Health Unit, McGill University Health Centre, Director: S. S. D. – co-author). Applanation tonometry (SphygmCor, AtCor Medical) was used to measure carotid-femoral pulse wave velocity (cPWV), the gold standard measurement assessing central arterial stiffness, as well as carotid-radial pulse wave velocity (crPWV), which is a measure of peripheral stiffness. Specifically, cPWV and crPWV were measured in triplicates (and averaged out) using a high-fidelity micromanometer on the tip of a hand-held tonometer (SPC-301; Millar Instruments), which was applied over the carotid and femoral (or radial) arteries, and a 3-lead electrocardiogram. To minimise variability between replicate measurements, we discarded PWV measures that had consecutive readings with a difference that was >0.5 m/s\(^\text{42}\). PWV measures with individual-site (carotid or femoral) electrocardiogram (ECG)-pulse transit time so >5% and overall so >10% were discarded and the measurement was repeated. PWV with a heart rate difference between the carotid and the femoral site of ≥5 beats/min were also rejected, and the measurement was repeated. Only high-quality measurements were accepted. After measuring the distance between the recording sites, the PWV was calculated (PWV = distance (m)/transit time (s))\(^\text{43–47}\). To minimise the effect of the circadian cycle, assessments were performed at the same time in the morning at each visit (online Supplementary Table S1).

**Biomarkers.** Fasting blood samples were collected between 07.00 and 10.00 hours at baseline and final visits to minimise any variation owing to biological rhythms of most biomarkers. Ionised Ca was analysed within 30 min of sampling at the Division of Biochemistry at the Montreal General Hospital (MGH) using the ABL 800 series blood gas analyser (Radiometer America), with an intra-individual % CV of 2.8% based on internal quality controls for ionised Ca. The remaining blood samples were separated into plasma and serum fractions and stored at −80°C until further analysis. Measurements of total cholesterol, HDL-cholesterol, TAG, apo-A1 and apo-B, and high-sensitivity C-reactive protein (hsCRP) were performed using Synchron LX Systems (Beckman Coulter Inc.) at the end of the trial period in one single batch at the MGH. The intra-assay % CV was 0.7% for total cholesterol, 0.6% for TAG, 1.5% for HDL-cholesterol, 0.9% for apo-A1, 1% for apo-B and 0.9% for hsCRP. LDL-cholesterol was calculated using the Friedewald equation\(^\text{48}\). Plasma total 25-hydroxy vitamin D (25(OH)D) and parathyroid hormone (PTH) concentrations were measured using an autoanalyzer (Liaison, DiaSorin) with an intra-assay CV of 4.1 and 3.6%, respectively. All 25(OH)D and PTH measurements were performed at the School of Dietetics and Human Nutrition of McGill University, which participated in the international Vitamin D External Quality Assessment Program (http://www.deqas.org) and obtained a certificate of proficiency for 2011–2015 (Director: H. A. W. – co-author). The accuracy of the methodology for vitamin D assays was assessed using the National Institutes of Standards and Technology Standard Reference Material (972a, level 1 and level 2). The accuracy of Liaison controls were 94.4–100.4% for 25(OH)D and 96.5–97.8% for PTH.

**Online feedback survey.** Following completion of this pilot trial, all participants were invited to complete an online feedback survey – ‘Participation in Pilot Calcium Study: Feedback Survey’ – anonymously using LimeSurvey application (http://www.limesurvey.org). The survey aimed to evaluate the acceptability of the trial interventions, participant satisfaction with the dietary modifications, supplement regimen, trial visits and procedures, as well as monthly contacts with the dietitian. The survey included an open-ended question for the participants’ feedback on the strengths and limitations of the trial design.
Statistical analyses

Summary statistics were computed for baseline characteristics, presented as mean values and standard deviations for normally distributed continuous variables or as counts and percentages for categorical variables. The χ² test was used to test for differences in proportions. Independent Student's t tests were used to compare the differences in mean intakes of dietary Ca and vitamin D at 1, 6 and 12 months between the two intervention groups. Independent Student's t tests were also used to compare the differences in blood pressure, anthropometric measurements, physical activity, vascular and bone biomarkers at 12 months and over time. Within- and between-group differences over time in ePWV were examined using repeated-measures ANOVA, as per intention-to-treat analysis. Owing to the exploratory nature of the trial and small sample size, no multiple-testing correction was performed (49). Significance was set at P < 0·05. All statistical analyses were performed using the statistical software package SPSS version 22 for Windows (SPSS Inc.).

Results

The Consolidated Standards of Reporting Trials (CONSORT) flow chart depicting participant selection process is demonstrated in Fig. 1. In total, thirteen women were enrolled for the trial between July 2012 and February 2013 at a mean age of 63·2 (sd 6·6) years, BMI of 24·6 (sd 2·9) kg/m², systolic blood pressure of 111·1 (sd 13·0) mmHg and diastolic blood pressure of 71·3 (sd 10·1) mmHg. Among them, seven participants were randomised to the CaSuppl group and six participants to the CaDiet group. In total, three participants withdrew from the trial and one was lost to follow-up. Dropout rates were similar between groups. Of the four participants who did not complete the trial, one withdrew from the trial when her family doctor initiated her on antihypertensive medication within 2 months following randomisation; her blood pressure at randomisation was within normal limits. We were unable to ascertain her blood pressure as she did not return for on-site visits and we were unsuccessful in contacting her physician.

No differences in baseline characteristics were observed between the two groups with regard to age, anthropometric variables, physical activity level, nutrient intakes including Ca and vitamin D, or vascular variables (Table 1). The only statistically significant difference between groups was a higher reported family history of stroke in the CaSuppl group (P = 0·03).

In all, nine participants completed all telephone follow-ups and on-site visits. Dietary data derived from the multiple-pass 24-h recalls indicated that both the CaSuppl group and the CaDiet group participants were within 20% of their calculated Ca intake target over the trial period (94–113 and 96–116%, respectively). The calculated average dietary Ca intake from the multiple-pass 24-h recalls indicated that the CaSuppl group had significantly lower mean intakes (480 (sd 292) mg/d at 1 month, 400 (sd 70) mg/d at 6 months and 600 (sd 95) mg/d at 12 months) than the CaDiet group (1380 (sd 437) mg/d at 1 month, 1269 (sd 188) mg/d at 6 months and 1019 (sd 323) mg/d at 12 months) (P < 0·05; Fig. 2). During the 12-month intervention, the CaSuppl group had a significantly lower intake of dietary vitamin D at 6 months (1·54 vs. 1·18 μg) (P < 0·05). The 12-month average total Ca intake (dietary + supplemental Ca) in the CaSuppl group was 1124 μg/d, whereas in the CaDiet group, we found no significant differences (P = 0·13). When we compared the usual dietary Ca intake data derived from the Harvard–Willet FFQ, there was a significant between-group difference at 12 months (P = 0·04). However, the mean dietary Ca intake was 761 (sd 277) mg/d in the CaSuppl group and 1187 (sd 232) mg/d in the CaDiet group. Mean dietary vitamin D intakes derived from the FFQ method at 12 months were 3·42 (sd 1·50) μg/d and 10·43 (sd 4·28) μg/d in the CaSuppl and the CaDiet groups, respectively. Overall adherence rate to Ca supplements was 85% in the CaSuppl group, and adherence rate to vitamin D supplements was 98% in both groups. None of the participants reported adverse events from supplements.

We found no significant differences in body weight, BMI, waist circumference, waist:hip ratio or physical activity level between the intervention groups at 12 months, and no significant within-group change over time was observed (P > 0·05).

Following the 12-month intervention, no significant differences in blood pressure or vascular health biomarkers were found between groups or within groups over time (Table 2). We observed that the systolic blood pressure was higher in the CaSuppl group compared with the CaDiet group at 12 months, although not reaching statistical significance (P = 0·05). Systolic blood pressure values were normal in both groups at 12 months. Similarly, we observed a mean increase of 8·6 mmHg in diastolic blood pressure in the CaSuppl group, a mean increase of 1 mmHg in the CaDiet group, but the between-group change over time was not statistically significant (P = 0·07). Diastolic blood pressure values were normal in both
Table 1. Baseline characteristics of thirteen participants by intervention group
(Mean values and standard deviations; number of participants and percentages)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>CaSuppl (n 7)</th>
<th>CaDiet (n 6)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>65.0 ± 4.2</td>
<td>60.8 ± 8.5</td>
<td>0.26</td>
</tr>
<tr>
<td>Caucasian</td>
<td>4/57.1</td>
<td>5/83.3</td>
<td>0.31</td>
</tr>
<tr>
<td>Menarche age (years)</td>
<td>13.0 ± 1.4</td>
<td>12.5 ± 1.87</td>
<td>0.59</td>
</tr>
<tr>
<td>Menopause age (years)</td>
<td>49.3 ± 5.8</td>
<td>47.5 ± 6.8</td>
<td>0.62</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.6 ± 8.4</td>
<td>24.6 ± 8.1</td>
<td>0.10</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
<td>97.8 ± 7.9</td>
<td>98.6 ± 2.4</td>
<td>0.80</td>
</tr>
<tr>
<td>Waist:hip ratio</td>
<td>0.83 ± 0.03</td>
<td>0.83 ± 0.07</td>
<td>0.98</td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic (mmHg)</td>
<td>114 ± 16</td>
<td>108 ± 8</td>
<td>0.38</td>
</tr>
<tr>
<td>Diastolic (mmHg)</td>
<td>70 ± 13</td>
<td>73 ± 5</td>
<td>0.71</td>
</tr>
<tr>
<td>Arterial stiffness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cfPWV (m/s)</td>
<td>7.68 ± 1.4</td>
<td>7.87 ± 2.2</td>
<td>0.85</td>
</tr>
<tr>
<td>crPWV (m/s)</td>
<td>7.67 ± 0.8</td>
<td>8.16 ± 1.4</td>
<td>0.43</td>
</tr>
<tr>
<td>Calcium (mmol/l)</td>
<td>1.26 ± 0.3</td>
<td>1.27 ± 0.3</td>
<td>0.56</td>
</tr>
<tr>
<td>25(OH)D (nmol/l)</td>
<td>60.2 ± 25.2</td>
<td>63.4 ± 36.0</td>
<td>0.85</td>
</tr>
<tr>
<td>PTH (pmol/l)</td>
<td>31.1 ± 11.1</td>
<td>24.7 ± 11.2</td>
<td>0.33</td>
</tr>
<tr>
<td>Family history</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoporosis n</td>
<td>4</td>
<td>2</td>
<td>0.39</td>
</tr>
<tr>
<td>CHD n</td>
<td>4</td>
<td>2</td>
<td>0.39</td>
</tr>
<tr>
<td>Stroke n</td>
<td>4</td>
<td>0</td>
<td>0.03</td>
</tr>
<tr>
<td>Dyslipidaemia n</td>
<td>3</td>
<td>5</td>
<td>0.14</td>
</tr>
<tr>
<td>Hypertension n</td>
<td>3</td>
<td>5</td>
<td>0.14</td>
</tr>
<tr>
<td>Diabetes n</td>
<td>3</td>
<td>2</td>
<td>0.73</td>
</tr>
<tr>
<td>Physical activity (MET-min/week)</td>
<td>3320</td>
<td>1502</td>
<td>0.33</td>
</tr>
<tr>
<td>Dietary intake (per d)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Energy (kJ)</td>
<td>10496</td>
<td>9471</td>
<td>0.49</td>
</tr>
<tr>
<td>Ca (mg)</td>
<td>1054</td>
<td>1170</td>
<td>0.42</td>
</tr>
<tr>
<td>Vitamin D (µg)</td>
<td>15.6</td>
<td>12.3</td>
<td>0.47</td>
</tr>
</tbody>
</table>

CaSuppl, Ca supplement group; CaDiet, Ca diet group; cfPWV, carotid-femoral pulse wave velocity; crPWV, carotid-radial pulse wave velocity; iCalcium, ionised Ca; 25(OH)D, 25-hydroxyvitamin D; PTH, parathyroid hormone; MET, metabolic equivalent.

* Dietary data derived from the Harvard–Willett semi-quantitative FFQ.

Fig. 2. Mean energy (a), dietary calcium (b) and dietary vitamin D (c) intake over time. Values are means, with 95% CI represented by vertical bars. Mean value was significantly different from that of the calcium diet group (CaDiet): * P < 0.05, ** P < 0.01. ■, Ca supplement group; □, CaDiet.
groups at 12 months. Arterial stiffness measurements were completed with a mean duration of <45 min with each participant at each visit without adverse reactions. No between-group differences in cPWV or crPWV were observed over time (Fig. 3). A significant increase in crPWV was observed between 6 and 12 months in the CaDiet group (P = 0.03).

Plasma lipid concentrations did not differ significantly between CaSuppl and CaDiet following the 12-month intervention (Table 2). No significant difference in change over time between groups was observed with the exception of HDL-cholesterol, for which there was an increase of 0·20 mmol/l in CaSuppl and a decrease of 0·15 mmol/l in CaDiet (P = 0.02). Levels of apo-A1, apo-B and hsCRP did not differ significantly between intervention groups. No between-group differences at 12 months were observed in markers of bone health including ionised Ca, 25(OH)D, PTH and phosphate. There was a mean decrease of 0·03 mmol/l in 25(OH)D level was also observed in the CaDiet group (P = 0.007) and an increase of 0·57 pmol/l in PTH (P < 0.001) between baseline and end of trial in the CaDiet group. A mean decrease of 3·70 mmol/l in 25(OH)D level was also observed in the CaDiet group, but this was not statistically significant (P = 0.33) (Table 3).

Responses from the online survey (n = 8) showed that all participants found the adherence to daily supplementation easy. Although only 25 % of the CaDiet group reported having difficulty meeting the daily dietary Ca target of three portions of dairy products and alternatives, all the participants from the CaSuppl group found it challenging to adhere to the dietary restriction of one small portion of Ca-rich food a day. Reasons provided by CaSuppl participants encountering difficulties included ‘not being able to eat some favourite foods’ or had to ‘reduce some of the regularly consumed foods significantly’. Moreover, one participant felt that ‘it was difficult to measure some foods’ to adequately report the portion consumed during telephone follow-ups. Overall, all participants felt adequately informed on how to modify their intake of dietary Ca from the baseline nutritional education session and the monthly follow-ups.

**Discussion**

Our pilot trial demonstrated the feasibility of conducting a large-scale, randomised-controlled trial to estimate the effect of supplemental Ca as compared with dietary Ca on vascular and bone health in postmenopausal women. In particular, we

**Table 2. Changes in blood pressure and vascular health biomarkers from baseline to the end of the trial (12 months) (Mean values and standard deviations)**

<table>
<thead>
<tr>
<th></th>
<th>CaSuppl (n = 5)</th>
<th>CaDiet (n = 4)</th>
<th>P (CaSuppl v. CaDiet at 12 months)</th>
<th>P (ΔCaSuppl v. ΔCaDiet)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>12 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cPWV (m/s)</td>
<td>8.25 ± 1.09</td>
<td>8.70 ± 1.80</td>
<td>8.71 ± 2.08</td>
<td>7.30 ± 1.10</td>
</tr>
<tr>
<td>crPWV (m/s)</td>
<td>7.45 ± 0.82</td>
<td>7.60 ± 0.90</td>
<td>8.55 ± 1.45</td>
<td>8.60 ± 0.90</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>113 ± 18.8</td>
<td>125 ± 15.0</td>
<td>103 ± 6.8</td>
<td>104 ± 9.0</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>76 ± 14.1</td>
<td>76 ± 14.0</td>
<td>70 ± 5.1</td>
<td>70 ± 6.0</td>
</tr>
<tr>
<td>Cholesterol (mmol/l)</td>
<td>5.39 ± 1.02</td>
<td>5.75 ± 0.51</td>
<td>6.14 ± 0.38</td>
<td>6.10 ± 0.84</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>0.93 ± 0.56</td>
<td>1.22 ± 0.87</td>
<td>0.68 ± 0.28</td>
<td>0.80 ± 0.38</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/l)</td>
<td>1.78 ± 0.77</td>
<td>1.98 ± 0.81</td>
<td>1.99 ± 0.53</td>
<td>1.84 ± 0.41</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/l)</td>
<td>3.19 ± 0.98</td>
<td>3.25 ± 0.61</td>
<td>3.00 ± 1.95</td>
<td>3.90 ± 1.04</td>
</tr>
<tr>
<td>Apo-A1 (g/l)</td>
<td>1.31 ± 0.75</td>
<td>1.76 ± 0.33</td>
<td>1.65 ± 0.35</td>
<td>1.59 ± 0.28</td>
</tr>
<tr>
<td>Apo-B (g/l)</td>
<td>1.04 ± 0.33</td>
<td>1.07 ± 0.26</td>
<td>1.17 ± 0.24</td>
<td>1.20 ± 0.32</td>
</tr>
<tr>
<td>hsCRP (mg/l)</td>
<td>1.68 ± 1.71</td>
<td>0.76 ± 0.49</td>
<td>0.33 ± 0.15</td>
<td>0.38 ± 0.24</td>
</tr>
</tbody>
</table>

cPWV, carotid-femoral pulse wave velocity; crPWV, carotid-radial pulse wave velocity; SBP, systolic blood pressure; DBP, diastolic blood pressure; hsCRP, high-sensitivity C-reactive protein; Δ, before and after intervention comparisons.

Fig. 3. Change in arterial stiffness markers, (a) carotid-femoral pulse wave velocity (cPWV) (P<sub>time × intervention</sub> = 0.16) and (b) carotid-radial pulse wave velocity (crPWV) (P<sub>time × intervention</sub> = 0.93), over time. Values are means, with 95 % CI. ——, Calcium supplement group; - - - - - - , calcium diet group.
demonstrated that the combination of an initial in-person nutritional counselling session and monthly telephone follow-ups was effective to ensure participant adherence to the dietary aspects of the trial protocol. Participants felt that the monthly contacts with the dietician were efficient to help them maintain the proper dietary Ca intake throughout the trial. In addition, we were able to demonstrate the feasibility in conducting the visits and a comprehensive set of vascular tests without adverse reactions or unforeseen problems.

Preliminary results from this pilot trial did not show any differential effects of Ca supplementation as compared with dietary Ca on arterial stiffness or on vascular health biomarkers. However, the CaSuppl average dietary Ca intake estimated from dietary Ca in each group at monthly follow-ups was effective to help achieve the target dietary Ca intake. Milk and dairy products were most often consumed by the participants in this feasibility trial to meet their intervention targets. Although the Harvard–Willett FFQ includes a section to assess the intake of milk and dairy products, it does not discriminate soft or semi-soft cheeses from firm or hard cheeses. Similarly, this semi-quantitative FFQ does not include Ca-rich items that are currently commonly consumed, such as Greek yogurts, beverages enriched with Ca, canned salmon with bones, pizza and mixed dishes prepared with milk or dairy products. Given the popular consumption of these listed items by the participants in our feasibility trial, a short comprehensive Ca-focused semi-quantitative FFQ may improve the estimation of usual dietary Ca intake, and likely decrease respondent burden.

Thus far, observational and ancillary studies have investigated the possible relationship between Ca supplements and cardiovascular events following the publication of a meta-analysis of Ca intervention trials(13) and a secondary analysis of the Women’s Health Initiative Ca/vitamin D supplementation study’s data set(56). More specifically, Bolland et al.(13) demonstrated an increased risk of myocardial infarction in individuals who received Ca supplements alone (hazard ratio (HR) 1.31; 95% CI 1.02, 1.67) or with vitamin D (HR 1.21; 95% CI 1.01, 1.44) based on self-reported and verified myocardial infarctions. In contrast, a recent meta-analysis of published and unpublished results from randomised-controlled trials of women only by Lewis et al.(57) demonstrated an absence of increased risk for CHD (relative risk (RR) 1.02; 95% CI 0.96, 1.09) or all-cause mortality (RR 0.96; 95% CI 0.91, 1.02) from Ca supplements with or without vitamin D in elderly women. Yet, the evidence remains conflicting, which may be due to the primary investigated end point of randomised-controlled trials not being related to cardiovascular risks and an oversight on the assessment of dietary Ca intake(17,18,57–59).

Observational studies suggest an association between higher serum Ca concentrations and carotid artery plaque thickness(60), increased risk of myocardial infarction and stroke(61) in older men and women. An increase in total serum Ca level of 0.1 mmol/l has been reported to be associated with 23% higher odds of abdominal aortic calcification in postmenopausal women(62). Furthermore, it has been previously shown that

Table 3. Changes in ionised calcium (iCalcium), 25-hydroxyvitamin D (25(OH)D) and parathyroid hormone (PTH) from baseline to the end of the trial (12 months) (Mean values and standard deviations)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>12 months</th>
<th>P (CaSuppl v. CaDiet at 12 months)</th>
<th>P (ΔCaSuppl v. ΔCaDiet)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
<td>SD</td>
</tr>
<tr>
<td>iCalcium (mmol/l)</td>
<td>1.25</td>
<td>0.04</td>
<td>1.26</td>
<td>0.03</td>
</tr>
<tr>
<td>25(OH)D (nmol/l)</td>
<td>54.1</td>
<td>26.6</td>
<td>63.6</td>
<td>13.9</td>
</tr>
<tr>
<td>PTH (pmol/l)</td>
<td>3.50</td>
<td>1.33</td>
<td>2.89</td>
<td>0.72</td>
</tr>
<tr>
<td>Phosphate (mmol/l)</td>
<td>1.30</td>
<td>0.16</td>
<td>1.27</td>
<td>0.11</td>
</tr>
</tbody>
</table>

Δ, Before and after intervention comparisons.
ionised Ca concentrations increase acutely following supplementation with 1000 mg of Ca\(^{(63,64)}\), although whether these observed changes are maintained with chronic Ca supplement use is unknown. Reid et al. speculate that the increase in serum ionised Ca concentrations may lead to a sequence of events contributing to the acceleration of vascular disease by Ca supplementation. They hypothesised that the pathogenic pathway leading to progressive arterial calcification is via a loss of inhibition of mineralisation due to increased complexing of ionised Ca with pyrophosphate\(^{(65)}\), reduced inhibition of arteriosclerotic signalling in vascular smooth muscle cells due to decreased PTH levels\(^{(58)}\) and increased binding to Ca-sensing receptors on vascular smooth muscle cells and platelets\(^{(65)}\). Increased arterial stiffness and impaired endothelial vasodilator function resulting from high circulating levels of ionised Ca associated with Ca supplementation could also lead to vascular damage\(^{(58)}\). However, Burt et al.\(^{(64)}\) examined the acute effect of 1000 mg of Ca citrate on arterial stiffness in adults aged 50 years and above and found no significant change in PWV 3 h following supplementation.

Arterial stiffness, as measured by the ‘gold-standard’ cfpPWV, is an overall indicator of vascular health and is strongly associated with the development of atherosclerosis at different sites of the arterial system and CVD and cardiovascular events\(^{(28,29,66,77)}\). An increase in cfpPWV by 1 m/s corresponds to an adjusted risk increase of 14, 15 and 15% in total cardiovascular events, cardiovascular mortality and all-cause mortality, respectively\(^{(160)}\). Using this gold standard measure, dairy food intake has been shown to have a favourable effect on arterial stiffness, as well as overall cardiovascular profile and reduced mortality\(^{(68–71)}\). However, the evidence regarding the effect of Ca in the form of supplements on arterial stiffness is less consistent. When administered to healthy volunteers, Ca citrate (single oral dose of 1000 mg, measurements at times 0, 60, 120 and 180 min) was observed to cause an acute increase in total and ionised Ca (by an average of 0-10 and 0-06 mmol/l, respectively) and a decrease in PTH\(^{(64)}\). However, the acute increase in Ca was associated with reduced arterial wave reflection, which in the long-term may reduce cardiovascular risk\(^{(64)}\). In an acute loading cross-over trial, 600 mg of Ca from dairy products did not produce any differential effect on arterial stiffness in young, healthy subjects 2 h after each challenge\(^{(72)}\). In our pilot trial, Ca supplements did not affect blood pressure, cfpPWV or crPWV differently than dietary Ca throughout the 12-month intervention.

The effect of Ca supplementation on serum lipids is inconsistent in the literature. Some studies report that supplemental Ca may cause beneficial changes in circulating lipids\(^{(73,74)}\), whereas several studies found no effect\(^{(75–78)}\). In contrast, Ca supplementation as compared with placebo for 12 months improved the lipid profile in a randomised-controlled trial of postmenopausal women, and this improvement was still observed at the 3-year follow-up\(^{(73)}\). Dairy foods have been reported to have either neutral or beneficial effects on blood lipid profile\(^{(79–82)}\). In contrast, supplemental Ca in the form of calcium carbonate did not exert such an effect on blood lipid concentrations\(^{(78)}\). In this study, we observed an increase in HDL-cholesterol in the supplement intervention group but no other change in blood lipid profile. An increase in HDL-cholesterol concentration following Ca supplementation has been reported in the literature\(^{(73,83,84)}\), and may likely be a result of the complexing of fatty and bile acids by Ca the intestinal tract\(^{(73,85)}\).

Although our trial provides enough information to ascertain the feasibility of a larger randomised-controlled trial, it is limited by its small sample size, and therefore prevents conclusions regarding effects of the Ca interventions on vascular parameters. Although we experienced a dropout rate of 30% (four out of thirteen participants), in keeping with other randomised-controlled trials of Ca interventions\(^{(53,73,86)}\), there were no differential dropout rates between the trial groups. Motivational interviewing techniques and participant satisfaction should be emphasised immediately following intervention initiation to improve participant retention, as this pilot trial shows that the first few months were critical times for dropout. An adequately powered clinical trial is warranted to effectively elucidate the effect of supplemental Ca on vascular health in postmenopausal women, and is currently underway by our group (ClinicalTrials.gov number, NCT01731340). Given that we have modified the procedures based on the online feedback survey of participants after the completion of the pilot trial, we anticipate a lower dropout rate in our ongoing randomised-controlled trial.

In conclusion, the findings of this 12-month pilot trial indicate that both diet modifications and supplemental interventions were associated with high compliance and tolerance, demonstrating the feasibility of the interventions. Although limited by a small sample size, the results suggest that following this 12-month intervention, supplemental Ca does not exert a different effect than dietary Ca on vascular or bone health markers in healthy postmenopausal women. Nevertheless, the current state of uncertainty warrants further research to assess the effect of supplemental \(v\) dietary Ca on the development of CVD disease and whether this effect is mediated through established cardiovascular markers. In this context, results of an adequately powered randomised-controlled trial will facilitate the development of public health recommendations regarding Ca supplementation. Building on our findings of the feasibility of trial interventions, a randomised-controlled trial is currently ongoing by our group.

**Acknowledgements**

The authors thank the participants of the trial as well as Euro-Pharma who graciously provided the Ca and vitamin D supplements for this pilot trial.

The present trial was supported by the Fonds de recherche du Québec – Santé (FRQS) – Subvention d’établissement de jeunes chercheurs – 2011. The FRQS had no role in the design, analysis or writing of this article.

All named authors have made substantial contribution to the published manuscript as follows: S. N. M., D. G., S. S. D. and H. A. W. contributed to the design of the trial. M. W. and R. H. contributed to the recruitment of participants, collection of the data and statistical analysis. J. G. also contributed to
collection of the data and laboratory work. A. M. O. contributed to collection of the data, statistical analysis, interpretation of the data and writing of the manuscript. H. A. W., S. N. M. and S. S. D. also contributed to interpretation of the data and writing of the manuscript. All the authors read and approved the final version of the manuscript.

The authors report no conflicts of interest.

Supplementary material

For supplementary material/s referred to in this article, please visit http://dx.doi.org/doi:10.1017/S0007114516001677

References


42. AtCor Medical (2006) Software Operator’s Guide: Pulse Wave Analysis System SCOR-Px. Sydney: AtCor Medical.


